Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03095807 · ClinicalTrials.gov registry record · Phase 1
Investigation of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With Obesity
A Phase 1 study, sponsored by Novo Nordisk A/S.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
NCT03095807 is a Phase 1 study that has completed, run by Novo Nordisk A/S. The registered enrollment target is 34 participants.
The verdict
NCT03095807, a Phase 1 study, has completed, sponsored by Novo Nordisk A/S.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
Study Summary
This trial is conducted in the United States of America (USA). The aim of this trial is to assess the safety and tolerability of single doses of NNC9204-1706 administered subcutaneously in male subjects being overweight or with obesity.
Interventions
- DRUG Placebo
- DRUG NNC9204-1706 A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2017-03-20 |
| Est. Completion | 2017-08-31 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03095807
The ClinicalTrials.gov registry entry for NCT03095807 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03095807 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03095807 about?
NCT03095807 is a clinical study titled "Investigation of Single Ascending Doses of NNC9204-1706 in Male Subjects Being Overweight or With Obesity". This trial is conducted in the United States of America (USA). The aim of this trial is to assess the safety and tolerability of single doses of NNC9204-1706 administered subcutaneously in male subjects being overweight or with obesity.
What is the current status of trial NCT03095807?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2017-03-20. Estimated completion is 2017-08-31.
What interventions are being tested in trial NCT03095807?
The interventions under investigation include: Placebo (DRUG), NNC9204-1706 A (DRUG).
Who is sponsoring clinical trial NCT03095807?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.